Results 51 to 60 of about 51,875 (217)

New and Emerging Artificial Urinary Sphincters for Male Stress Urinary Incontinence: From Gold Standard to Next Generation

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction For more than four decades, the AMS‐800 has remained the clinical benchmark device for the treatment of male stress urinary incontinence (SUI). Although it remains the gold standard for male SUI, the AMS‐800 has continued to have limitations such as suboptimal post‐operative continence rates, fixed hydraulic pressure, need for ...
Erin C. Schnell, Connie N. Wang, Eric S. Rovner   +2 more
wiley   +1 more source

Sigma Factor F does not Prevent Rifampin Inhibition of RNA Polymerase or Cause Rifampin Tolerance in Mycobacterium tuberculosis

, 2010
The tolerance of Mycobacterium tuberculosis to anti-tuberculosis drugs is a major reason for the lengthy therapy needed to treat a tuberculosis infection.
Cole, Stewart T, Jeffrey M. Chen, Stewart T. Cole, Hartkoorn, Ruben C, Sala, Claudia, Magnet, Sophie J, Ruben C. Hartkoorn, Florence Pojer, Pojer, Florence, Claudia Sala, Sophie J. Magnet, Chen, Jeffrey M, Hartkoorn, Ruben C., Chen, Jeffrey M., Cole, Stewart T., Hartkoorn RC, Sala C, Chen JM, Magnet SJ, Magnet, Sophie J., Cole ST, Pojer F   +21 more
core   +1 more source

Staphylococcal response to daptomycin in implant-associated infections [PDF]

, 2011
The use of medical devices carries the risk of infection. Due to the development of multi-resistant bacteria, missing microcirculation, and biofilm embedded bacteria these implant-associated infections are difficult to treat.
John, Anne-Kathrin
core   +1 more source

Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia

Emerging Infectious Diseases, 2016
Few studies have examined whether the Xpert MTB/RIF test improves time to treatment initiation for persons with multidrug-resistant tuberculosis (MDR TB). We determined the impact of this test in Latvia, where it was introduced in 2010. After descriptive
Helen R. Stagg, Peter A. White, Vija Riekstiņa, Andra Cīrule, Ģirts Šķenders, Vaira Leimane, Liga Kuksa, Gunta Dravniece, James Brown, Charlotte Jackson   +9 more
doaj   +1 more source

Repurposing 9-Aminoacridine as an Adjuvant Enhances the Antimicrobial Effects of Rifampin against Multidrug-Resistant Klebsiella pneumoniae

Microbiology Spectrum, 2023
The increasing occurrence of extensively drug-resistant and pan-drug-resistant K. pneumoniae has posed a serious threat to global public health. Therefore, new antimicrobial strategies are urgently needed to combat these resistant K.
Pengfei She, Yimin Li, Zehao Li, Shasha Liu, Yifan Yang, Linhui Li, Linying Zhou, Yong Wu   +7 more
doaj   +1 more source

Pharmacokinetic and Pharmacodynamic Interactions Between Anti‐Asthma Drugs and Medicinal Plants: A Comprehensive Review

Phytotherapy Research, EarlyView.
ABSTRACT Asthma affects 260–300 million people worldwide. About 20%–35% of patients use medicinal plants with their asthma medication, often without telling their clinicians. Disclosure rates are low; up to 42% of asthma outpatients use herbal products, with no records in their charts.
Emine Kocyigit, Aylin Bülbül, Betul Kocaadam‐Bozkurt, Osman Bozkurt, Duygu Ağagündüz, Raffaele Capasso   +5 more
wiley   +1 more source

Influence of Single Nucleotide Polymorphisms on Rifampin Pharmacokinetics in Tuberculosis Patients

Antibiotics, 2020
Rifampin (RF) is metabolized in the liver into an active metabolite 25-desacetylrifampin and excreted almost equally via biliary and renal routes. Various influx and efflux transporters influence RF disposition during hepatic uptake and biliary excretion.
Levin Thomas, Sonal Sekhar Miraj, Mallayasamy Surulivelrajan, Muralidhar Varma, Chidananda S. V. Sanju, Mahadev Rao   +5 more
doaj   +1 more source

Rifampin (INN Rifampicin) [PDF]

Journal of Pain and Symptom Management, 2015
Therapeutic Reviews aim to provide essential independent information for health professionals about drugs used in palliative and hospice care. Additional content is available on www.palliativedrugs.com. Country-specific books (Hospice and Palliative Care Formulary USA, and Palliative Care Formulary, British and Canadian editions) are also available and
Paul, Howard, Robert, Twycross, Graham, Grove, Sarah, Charlesworth, Mary, Mihalyo, Andrew, Wilcock   +5 more
openaire   +2 more sources

Feasibility and clinical outcomes of routine point‐of‐care screening for opportunistic infections among people with advanced HIV disease in Guyana

HIV Medicine, EarlyView.
Abstract Objectives We evaluated the feasibility and outcomes of implementing comprehensive Point‐of‐care (POC) opportunistic infections (OIs) screening among people with Advanced HIV disease (AHD) in Guyana. Methods We conducted a prospective multicentre cohort study across seven sites between February 2024 and March 2025.
Antonio Camiro‐Zúñiga, Tariq Jagnarine, Divya Shivdas, Lakshmi Narain, Kwesi Vanccoten, Kampta Prashad, Abiola Jacobs, Quacy Grant, Mallika Mootoo, Narissa Lawerence, Suzanne Siebs, Escalada Rainier, Omar Sued, Freddy Perez   +13 more
wiley   +1 more source

Mean Rifapentine and Rifampin Serum Concentrations versus Time

, 2013
Mice were administered a single dose of 7.5, 10, 15, and 20 mg/kg of rifapentine or 10 mg/kg of rifampin. P, rifapentine; R, rifampin.
Kathy N Williams (37571), Ming Zhang (9736), Sandeep Tyagi (37573), Charles A Peloquin (37572), Andrew A Vernon (37574), Ian M Rosenthal (37570), William R Bishai (37575), Richard E Chaisson (37576), Jacques H Grosset (37577), Eric L Nuermberger (37578)   +9 more
core   +1 more source